Staphylococcus aureus bacteremia in patients with hematologic disorders

Area of Science:

• Infectious Diseases
• Hematology
• Clinical Microbiology

Background:

• Staphylococcus aureus bacteremia is a significant concern in patients with hematologic disorders.
• Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a prevalent pathogen, replacing methicillin-sensitive strains (MSSA) in recent years.
• Understanding the epidemiology and outcomes of S. aureus bacteremia in this vulnerable population is crucial.

Purpose of the Study:

• To analyze the incidence, sources, risk factors, and outcomes of Staphylococcus aureus bacteremia in patients with hematologic disorders over a 20-year period.
• To compare the clinical characteristics and survival rates between MRSA and MSSA bacteremia.
• To identify factors influencing MRSA acquisition and treatment efficacy.

Main Methods:

• Retrospective analysis of 27 S. aureus bacteremia episodes in 26 patients with hematologic disorders (1972-1991).
• Data collection included patient demographics, underlying hematologic conditions, primary and secondary foci, neutropenia status, colonization, and antibiotic exposure.
• Survival analysis was performed comparing MRSA and MSSA bacteremia outcomes.

Main Results:

• S. aureus bacteremia accounted for 6% of all bacteremia episodes in the hematology unit.
• MRSA became predominant over MSSA in the last four years of the study period.
• Common primary foci included skin and respiratory tract; most episodes occurred during neutropenia, with pharyngeal colonization preceding bacteremia. Antibiotic therapy predisposed to MRSA acquisition.
• Survival rates were comparable between MRSA and MSSA bacteremia, with all four MRSA patients receiving vancomycin surviving beyond one week. Secondary foci, mainly pulmonary, were observed in 30% of patients.

Conclusions:

• Staphylococcus aureus bacteremia, including MRSA, poses a significant risk in hematology patients, particularly during neutropenia.
• Vancomycin demonstrated effectiveness in treating MRSA bacteremia in this cohort.
• Prolonged antibiotic therapy may be warranted for patients with metastatic lesions, while abbreviated courses could be considered for neutropenic cancer patients.